• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom

March 30, 2022 By Sean Whooley

Abbott FreeStyle Libre Dexcom G6
Left: Abbott’s FreeStyle Libre CGM system. Right: Dexcom’s G6 CGM. [Images from Abbott and Dexcom, respectively]
Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress.

BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in continuous glucose monitors (CGMs) among type 2 diabetes non-intensive insulin therapy (T2 NIIT) patients.

Analysts Marie Thibault and Sam Eiber wrote in a report that they “came away more encouraged that the growing clinical and economic evidence and shifting society guidelines may translate into greater payor coverage in the next couple of years,” meaning we could see increased CGM adoption in this patient population for both Abbott and Dexcom. As such, BTIG lists both companies as “buy” options.

The report said that CGM coverage among public and private payors has expanded over recent years. In December 2021, the U.S. Centers for Medicare & Medicaid Services (CMS) announced expanded coverage for CGMs, ranging across all types of CGMs, including adjunctive and non-adjunctive CGMs, with CMS removing its requirement for four daily fingersticks to qualify for a CGM as well.

Dr. Gary Cohen said the trend over recent years has made insurance coverage for a CGM in basal-only patients more attainable. There have been successes in getting CGMs covered by Blue Cross Blue Shield of Massachusetts, AllWays for Mass General Brigham employees, Point32Health, and some Medicare Advantage plans. While Medicare coverage and other commercial payors have been varied, he reported that Medicaid remains challenging.

According to BTIG, Dr. Joshua Cohen feels the next steps for CMS include expanding coverage to basal-only and non-intensive patients, with recent changes to The American Diabetes Association (ADA) 2022 Standards of Care stretching its CGM recommendation to people on basal-only insulin.

The analysts said ongoing investments by Abbott and Dexcom on direct-to-consumer marketing and a salesforce targeting and educating primary care physicians (PCPs) may increase awareness and interest among both patients and providers.

“We think the most important factors for greater adoption are reimbursement and PCP education,” Thibault and Eiber wrote. “Dr. Cohen noted all of his motivated patients with diabetes would use a CGM if made available and that using a CGM does change their behavior. But, though his PCP peers are aware of CGMs, he believes it will take time for prescribing trends to change, as many PCPs do not prioritize learning about new technology.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS), CGM, Dexcom, Reimbursement

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS